KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$131.4 million.

  • Ionis Pharmaceuticals' Cash from Operations fell 1430.3% to -$131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.0 million, marking a year-over-year increase of 2981.45%. This contributed to the annual value of -$500.9 million for FY2024, which is 6290.27% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Cash from Operations of -$131.4 million as of Q3 2025, which was down 1430.3% from $151.3 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Cash from Operations' 5-year high stood at $203.7 million during Q4 2021, with a 5-year trough of -$200.2 million in Q4 2022.
  • For the 5-year period, Ionis Pharmaceuticals' Cash from Operations averaged around -$62.3 million, with its median value being -$97.4 million (2023).
  • In the last 5 years, Ionis Pharmaceuticals' Cash from Operations crashed by 61999.47% in 2021 and then surged by 22624.12% in 2025.
  • Ionis Pharmaceuticals' Cash from Operations (Quarter) stood at $203.7 million in 2021, then plummeted by 198.29% to -$200.2 million in 2022, then surged by 116.42% to $32.9 million in 2023, then crashed by 453.38% to -$116.1 million in 2024, then decreased by 13.17% to -$131.4 million in 2025.
  • Its last three reported values are -$131.4 million in Q3 2025, $151.3 million for Q2 2025, and -$150.8 million during Q1 2025.